Biodal (Vitamin D3 from Lichen)

Biodal is a trademarked vegan vitamin D3 (cholecalciferol) derived from lichen, delivering the same bioactive compound as animal-sourced D3. It exerts its effects through conversion to 25-hydroxyvitamin D in the liver and then to the active hormone 1,25-dihydroxyvitamin D (calcitriol) in the kidneys, which binds vitamin D receptors to regulate calcium absorption and immune gene expression.

Origin & History

Biodal is a branded vegan vitamin D3 (cholecalciferol) sourced from lichen, a symbiotic organism of fungi and algae that naturally produces cholecalciferol when exposed to sunlight. The lichen is wild-harvested from rocks and trees in North America, Asia, and Scandinavia or cultivated in controlled environments, then extracted using solvents like ethanol or water under pressure, purified, concentrated, and standardized into vegetable oil carriers such as MCTs.

Historical & Cultural Context

No historical or traditional medicinal use of lichen for vitamin D3 supplementation is documented in the research. Lichens are noted exclusively for modern vegan supplementation purposes, not traditional medicine systems.

Health Benefits

• Supports calcium homeostasis and bone health through vitamin D receptor activation (mechanism established for vitamin D3, no Biodal-specific clinical evidence)
• Regulates immune function through conversion to active 1,25-dihydroxyvitamin D (general vitamin D3 pathway, no lichen-specific trials)
• Provides bioequivalent vitamin D3 for vegans compared to lanolin-derived sources (claimed bioequivalence without dedicated trial data)
• Offers pesticide-free alternative to animal-derived vitamin D3 (quality claim without clinical comparison studies)
• Maintains vitamin D status in populations avoiding animal products (theoretical benefit, no Biodal-specific research)

How It Works

Biodal delivers cholecalciferol, which undergoes 25-hydroxylation by hepatic CYP2R1 and CYP27A1 enzymes to form 25-hydroxyvitamin D3 (calcidiol). Calcidiol is further hydroxylated in the kidneys by CYP27B1 (1-alpha-hydroxylase) to produce calcitriol (1,25-dihydroxyvitamin D3), the biologically active form. Calcitriol binds the nuclear vitamin D receptor (VDR), forming a heterodimer with the retinoid X receptor (RXR) that upregulates genes controlling intestinal calcium absorption via TRPV6 channels and calbindin-D9k, as well as immune-modulatory genes including cathelicidin.

Scientific Research

No specific human clinical trials, RCTs, or meta-analyses on Biodal or lichen-derived vitamin D3 were found in the research dossier. While general vitamin D3 research exists, no PubMed PMIDs or studies address Biodal uniquely; lichen D3 is presented as bioequivalent to lanolin-derived D3 without dedicated trial data.

Clinical Summary

Clinical evidence supporting Biodal specifically is absent in the published literature; all available data are extrapolated from trials using cholecalciferol regardless of source. Randomized controlled trials on cholecalciferol supplementation (400–4000 IU/day) in populations including postmenopausal women and older adults consistently show increases in serum 25-hydroxyvitamin D by 10–25 ng/mL and modest reductions in fracture risk when combined with calcium. A 2022 meta-analysis of 46 RCTs (n>49,000) found cholecalciferol more effective than ergocalciferol (D2) at raising serum 25(OH)D levels, supporting the use of D3-form products like Biodal. No head-to-head trials have compared lichen-derived D3 to lanolin-derived D3 for clinical endpoints, though chemical equivalence is assumed.

Nutritional Profile

Biodal is a concentrated vitamin D3 (cholecalciferol) extract derived from lichen (primarily Cladonia and Usnea species), standardized to deliver specific IU doses of vitamin D3 per serving — commonly formulated at 1,000–5,000 IU per unit dose depending on product application. As a micronutrient ingredient rather than a whole food, it contributes negligible macronutrients (protein, fat, carbohydrate near 0g at functional doses). The primary bioactive compound is cholecalciferol (vitamin D3, C27H44O), chemically identical to animal-derived vitamin D3 from lanolin, with a molecular weight of 384.64 g/mol. Lichen naturally biosynthesize vitamin D3 via UV exposure, making this one of the only plant-kingdom sources of true D3 (as opposed to D2/ergocalciferol found in fungi). Bioavailability is considered equivalent to lanolin-derived cholecalciferol, as the molecular structure is identical; absorption follows the same lipid-dependent pathway requiring dietary fat co-ingestion for optimal micellar incorporation, with estimated absorption efficiency of 50–80% under optimal conditions. Upon absorption, cholecalciferol undergoes hepatic hydroxylation to 25-hydroxyvitamin D [25(OH)D3] and subsequent renal conversion to the active metabolite 1,25-dihydroxyvitamin D3 (calcitriol). No significant co-occurring minerals or fiber are present at relevant concentrations in the purified extract. The ingredient is typically delivered in an oil-based carrier (e.g., sunflower or MCT oil) to enhance bioavailability, with the carrier contributing minor amounts of fatty acids depending on formulation.

Preparation & Dosage

No clinically studied dosage ranges for Biodal or lichen-derived D3 appear in available research. Producers note potential for 500 million 1000 IU doses annually from lichen cultivation, suggesting common supplemental dosing around 1000 IU, but without specific standardization details from clinical studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Calcium, Magnesium, Vitamin K2, Zinc, Boron

Safety & Interactions

Cholecalciferol from lichen (Biodal) carries the same safety profile as conventional vitamin D3; toxicity (hypercalcemia, hypercalciuria) is rare below 10,000 IU/day in healthy adults but risk increases with prolonged high-dose use. Biodal may interact with thiazide diuretics by amplifying hypercalcemia risk, and with calcipotriene or other vitamin D analogs by additive VDR activation. Patients on corticosteroids face accelerated 25(OH)D catabolism, potentially requiring higher doses, while those on antiepileptics (phenytoin, carbamazepine) may experience increased D3 metabolism via CYP3A4 induction. Biodal is considered safe in pregnancy at RDA levels (600 IU/day); doses above 4,000 IU/day during pregnancy should only be used under medical supervision.